GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (STU:NB3) » Definitions » 3-Year EPS without NRI Growth Rate

Neurocrine Biosciences (STU:NB3) 3-Year EPS without NRI Growth Rate : -11.50% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Neurocrine Biosciences 3-Year EPS without NRI Growth Rate?

Neurocrine Biosciences's EPS without NRI for the three months ended in Mar. 2024 was €0.29.

During the past 12 months, Neurocrine Biosciences's average EPS without NRI Growth Rate was 66.30% per year. During the past 3 years, the average EPS without NRI Growth Rate was -11.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 61.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Neurocrine Biosciences was 145.70% per year. The lowest was -58.60% per year. And the median was -14.35% per year.


Competitive Comparison of Neurocrine Biosciences's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's 3-Year EPS without NRI Growth Rate falls into.



Neurocrine Biosciences 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Neurocrine Biosciences  (STU:NB3) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Neurocrine Biosciences 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurocrine Biosciences (STU:NB3) Business Description

Traded in Other Exchanges
Address
12780 El Camino Real, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences (STU:NB3) Headlines

No Headlines